Background: Participants with prediabetes are at a high risk of developing type 2 diabetes (T2D). Recent studies have suggested that blocking the receptor activator of nuclear factor-κB ligand (RANKL) may improve glucose metabolism and delay the development of T2D. However, the effect of denosumab, a fully human monoclonal antibody that inhibits RANKL, on glycemic parameters in the prediabetes population is uncertain. We aim to examine the effect of denosumab on glucose metabolism in postmenopausal women with osteoporosis and prediabetes.

Methods: This is a 12-month multicenter, open-label, randomized controlled trial involving postmenopausal women who have been diagnosed with both osteoporosis and prediabetes. Osteoporosis is defined by the World Health Organization (WHO) as a bone mineral density T score of ≤ - 2.5, as measured by dual-energy X-ray absorptiometry (DXA). Prediabetes is defined as (i) a fasting plasma glucose level of 100-125 mg/dL, (ii) a 2-hour plasma glucose level of 140-199 mg/dL, or (iii) a glycosylated hemoglobin A1c (HbA1c) level of 5.7-6.4%. A total of 346 eligible subjects will be randomly assigned in a 1:1 ratio to receive either subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg every week for 12 months. The primary outcome is the change in HbA1c levels from baseline to 12 months. Secondary outcomes include changes in fasting and 2-hour blood glucose levels, serum insulin levels, C-peptide levels, and insulin sensitivity from baseline to 12 months, and the incidence of T2D at the end of the study. Follow-up visits will be scheduled at 3, 6, 9, and 12 months.

Discussion: This study aims to provide evidence on the efficacy of denosumab on glucose metabolism in postmenopausal women with osteoporosis and prediabetes. The results derived from this clinical trial may provide insight into the potential of denosumab in preventing T2D in high-risk populations.

Trial Registration: This study had been registered in the Chinese Clinical Trials Registry.

Registration Number: ChiCTR2300070789 on April 23, 2023. https://www.chictr.org.cn .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10726555PMC
http://dx.doi.org/10.1186/s13063-023-07769-0DOI Listing

Publication Analysis

Top Keywords

glucose metabolism
16
denosumab glucose
12
metabolism postmenopausal
12
postmenopausal women
12
12-month multicenter
8
multicenter open-label
8
open-label randomized
8
randomized controlled
8
controlled trial
8
women osteoporosis
8

Similar Publications

Purpose: To implement a low-rank and subspace model-based reconstruction for 3D deuterium metabolic imaging (DMI) and compare its performance against Fourier transform-based (FFT) reconstruction in terms of spectral fitting reliability.

Methods: Both reconstruction methods were applied on simulated and experimental DMI data. Numerical simulations were performed to evaluate the effect of increasing acceleration factors.

View Article and Find Full Text PDF

Metabolic syndrome prediction based on body composition indices.

J Egypt Public Health Assoc

December 2024

Department of Clinical Nutrition and Dietetics, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa, Jordan.

Background: Metabolic syndrome (MetS) is an important public health issue that has been lately linked as a growing concern worldwide.

The Objective: To find out which anthropometric and body composition indices can prognosticate MetS in Jordanian adult females.

Methods: A sample of 656 Jordanian adult females was recruited (January-March 2024) in the middle of Jordan.

View Article and Find Full Text PDF

Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease. The present work aimed to explore the function of regulator of Calcineurin 2 (RCAN2) in NAFLD and its related mechanisms. Mice were fed with high-fat diet (HFD) to construct NAFLD model.

View Article and Find Full Text PDF

Protective effects of different exercise modalities on oxidative stress in animal models of high intraocular pressure and diabetes.

Exp Eye Res

December 2024

Department of Biochemistry, Post-Graduate Program in Biochemistry and Post-Graduate Program in Pharmacology, Federal University of Santa Catarina (UFSC), Florianópolis, Santa Catarina, Brazil. Electronic address:

High intraocular pressure (HIOP) and high glucose levels are associated with oxidative stress. Although physical exercise protects against oxidative damage, its specific impact on eye health remains unclear. Thus, this study aimed to assess the impact of physical exercise on the oxidative status of whole eyes in male Swiss mice subjected to HIOP model and cafeteria diet (CD).

View Article and Find Full Text PDF

Semaglutide protects against diabetes-associated cardiac inflammation via Sirt3-dependent RKIP pathway.

Br J Pharmacol

December 2024

Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.

Background And Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert cardiovascular benefits in diabetic patients, but the underlying mechanisms remain incompletely understood. Semaglutide, a novel long-acting GLP-1RA, has shown a reduced risk of cardiovascular events. Based on these results, we investigated the therapeutic potential of semaglutide in diabetic cardiomyopathy and sought to elucidate the underlying mechanisms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!